CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-17). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 424 · Search date 2026-07-17 · Methodology v0.6

Polygala tenuifolia root extract,
does it really help with Improvement of memory, learning, and forgetfulness?

30-Second Summary
C
Evidence Grade C · 40 · Safety unknown
Small direct RCTs exist, but they are concentrated in one proprietary extract without independent replication
What the
research shows
BT-11 is a standardized root extract of Polygala tenuifolia. Two small double-blind RCTs were positive, but they came from the same research group, focused on the same proprietary ingredient, were short, and lack independent replication, placing the evidence at the bottom of C. It is not the unrelated drug also called BT-11 in inflammatory bowel disease research.
What the
ads claim
Marketing can connect traditional use for forgetfulness, acetylcholinesterase inhibition, and animal BDNF or neuroprotection findings to human memory improvement with generic Polygala capsules. Results from multi-herb formulas such as Guibi-tang or Ninjinyoeito are not evidence for Polygala alone.
*

Useful facts when choosing a product

  • In Korea, crude root, powders, extracts, and individually recognized Polygala-root extract powder are distinct products with different extraction methods and marker profiles.
  • The key human trials used the standardized proprietary ingredient BT-11 at about 300 mg/day, not ordinary Polygala tea.
  • The supplier describes BT-11 as its proprietary ingredient, so the trial results cannot automatically be applied to other Polygala extracts.
  • The cognitive-trial BT-11 is a standardized Polygala tenuifolia root extract and must not be confused with the unrelated BT-11 drug studied in inflammatory bowel disease.
  • Polygala is often combined with other herbs in traditional formulas, so efficacy and adverse effects of formulas must be separated from Polygala alone.
Gap Measurement · Verdict 424 · C 40
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Lee 2009 (PMID 19429065) identifies BT-11 as an extract of dried Polygala tenuifolia roots. The trial administered 300 mg/day for four weeks to healthy adults and reported placebo-adjusted improvement in K-CVLT immediate recall and SOPT errors. Most K-CVLT subtests improved in both groups, indicating a substantial practice effect. Shin 2009 (PMID 19699261) reported improved total CERAD and selected subtests in 28 BT-11 and 25 placebo participants, but follow-up was short. No adequately sized, long-term independent RCT was identified thereafter. An unrelated drug named BT-11 in inflammatory bowel disease must not be confused with this Polygala extract or misattributed to its evidence base.

02

Why this is classified as C (40)

Two direct RCTs rule out ? and D, but the same team, same proprietary ingredient, small samples, short duration, multiple tests, and absent independent replication place the evidence at the bottom of C with 40 points.

Counterpoint. An early positive signal remains for products matching BT-11 exactly, but it cannot be expanded to learning generally, dementia prevention, or daily functioning.

Rejudgment record. New verdict — Two small direct BT-11 RCTs recognized, but bottom-of-C because of the same team, one proprietary ingredient, and no independent replication

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Lee et al. 2009Randomized double-blind placebo-controlled trialUnknown; proprietary BT-11 ingredientK-CVLT and SOPTImmediate recall and SOPT errors improved versus placebo, but several K-CVLT scores improved in both groups.Key
Shin et al. 2009Randomized double-blind placebo-controlled trial53Unknown; proprietary BT-11 ingredientCERAD and MMSETotal CERAD and selected subtests improved more with BT-11, but follow-up was short.Key
AHRQ review 2017Systematic review of cognitive-decline preventionU.S. public agencyLong-term cognitive decline, MCI, and dementiaThe elderly BT-11 trial was excluded for inadequate follow-up.Boundary
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-17).

Lee JY, Kim KY, Shin KY, Won BY, Jung HY, Suh YH. Effects of BT-11 on memory in healthy humans. Neurosci Lett. 2009;454(2):111-114. PMID: 19429065. DOI: 10.1016/j.neulet.2009.03.024.
checked
Shin KY, Lee JY, Won BY, et al. BT-11 is effective for enhancing cognitive functions in the elderly humans. Neurosci Lett. 2009;465(2):157-159. PMID: 19699261. DOI: 10.1016/j.neulet.2009.08.033.
checked
Kane RL, Butler M, Fink HA, et al. Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia. Comparative Effectiveness Review No. 188. AHRQ Publication No. 17-EHC008-EF. 2017.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-17 · Corrections: none

Cite this verdict

Polygala tenuifolia root extract x memory, learning, and forgetfulness Evidence Grade C card
[Chamgap] Polygala tenuifolia root extract x memory, learning, and forgetfulness — Evidence Grade C·40. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/cognition/polygala-tenuifolia-root-extract-memory-learning/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.